FluoroPharma Medical, Inc. (FPMI)
FluoroPharma Medical, Inc. is a biopharmaceutical company focused on discovering and developing patented Positron Emission Tomography (PET) imaging products to improve patient management by evaluating cardiac disease at the cellular and molecular levels. The company is currently advancing two products in clinical trials to fulfill critical unmet medical needs. The agents will provide clinicians important tools for detecting and assessing pathology before critical manifestations of disease.
The company's proprietary molecules labeled with the radioactive isotope of fluorine combined with PET scanning provide non-invasive, highly specific and efficient assessment of heart metabolism and physiology. FluoroPharma's cardiovascular program addresses the largest segment of the nuclear medicine market.
Molecular imaging fulfills numerous unmet needs in diagnosis by enabling visualization, characterization and measurement of biological processes at the molecular and cellular level. Unlike traditional imaging modalities – MRI, CT, and Ultrasound – that reveal the anatomical abnormalities and cause for disease, PET provides insight into physiology and can detect disease before anatomical manifestation is identified. According to GAI, the market for molecular imaging agents currently exceeds $1.7 billion annually and promises rapid growth for the foreseeable future.
FluoroPharma's comprehensive technology platform was developed by scientists at the Massachusetts General Hospital. To date, the company has been issued four US patents and has seven applications pending in addition to strong international protection. With a solid and experienced management team in place and the necessary resources to advance clinical development, FluoroPharma is well positioned to capitalize on its superior imaging technology.
Omni Bio Pharmaceutical, Inc.
Omni Bio Pharmaceutical, Inc. is a clinical-stage biopharmaceutical company formed in 2006 to explore new methods of use of an FDA approved drug - Alpha-1 antitrypsin (AAT). AAT has a 20-year safety record as an approved treatment for emphysema in AAT-deficient patients. Omni Bio has their corporate headquarters in Greenwood Village, Colorado.
AAT is a naturally occurring anti-inflammatory protein. It is FDA approved and prescribed for emphysema and chronic obstructive pulmonary disorder (COPD) in AAT-deficient patients. AAT inhibits destructive enzymes such as proteinase-3. It is anti-complement, prevents maturation of antigen presentation, induces T-regulatory cells, and inhibits responses to inflammatory cytokines.
Omni Bio is the licensee of patent portfolios from the University of Colorado and a privately held company that include three issued patents and 24 patent applications. The patent portfolios consist of new methods of use for AAT. Currently, the Company is evaluating AAT for the treatment of Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza, and certain bacterial disorders, including anthrax exposure.
Earlier this year, Omni Bio purchased a 25 percent equity interest in a newly formed company, BioMimetix Pharmaceutical, Inc. BioMimetix was formed to develop a new class of patented compounds for the treatment of various disease and health care treatment classifications. This includes radiation toxicity incurred during the treatment of cancer. BioMimetix's research and development efforts are being performed under an exclusive license of an issued patent held by Duke University.
Osage Exploration and Development, Inc.
Osage Exploration and Development, Inc. is an independent exploration and production company that lists on the OTC Bulletin Board. The Company has interests in oil and gas wells and prospects in the United States and Colombia. Osage has their headquarters in San Diego, California, with production offices in Oklahoma City, Oklahoma and executive offices in Bogotá, Colombia.
The Company's business model in the United States is to evaluate and acquire acreage blocks in emerging plays where they can retain a significant interest and jointly drill and develop with industry partners. Osage Exploration's plan is to continue to add more and larger projects to their drilling/development portfolio and grow the Company organically through the application of their core competencies.
Osage Exploration's current focus is on developing their 12,000-acre Horizontal Mississippian block along the Nemaha Ridge in Logan County, Oklahoma, with their partners Slawson Exploration, and U.S. Energy Development Corp. Slawson Exploration is the Operator of the project and owns 45 percent, U.S. Energy Development owns 30 percent, and Osage Exploration has 25 percent.
Osage's operations in South America include the Guaduas Field and the Guaduas-La Dorada pipeline in Colombia. They are partners with Pacific Rubiales Energy, the largest Colombian independent oil and gas company, in both of these ventures. In Colombia, Osage owns the aforementioned pipeline that services a critical link for oil coming out of several parts of Colombia ultimately intended for the port at Covenas for export to the Gulf coast of the United States.